GO:0038027 apolipoprotein A-I-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038027 describes the biological process triggered when apolipoprotein A-I (ApoA-I) engages cellular acceptors and initiates intracellular signaling, most classically leading to cholesterol efflux.
• The pathway is best characterized in macrophages and other peripheral cells where ApoA-I, the major apolipoprotein of HDL, stimulates removal of excess cholesterol via ABCA1 and related transporters.
• ABCA1 is the central receptor/transporter in this pathway; its expression is transcriptionally controlled by LXR and post-transcriptionally by cellular cholesterol status.
• ABCA7 is a closely related transporter whose expression is regulated by cholesterol through SREBP2 and which participates in phagocytic and lipid-handling functions.
• Pharmacological and dietary interventions such as curcumin and emodin can enhance ApoA-I-mediated cholesterol efflux by upregulating ABCA1 or PPAR-gamma-dependent pathways.
• Dysregulation of this pathway is linked to atherosclerosis, cardiovascular disease, and age-related cerebral hypoperfusion, making it a key target for gene-editing and cell-model research.
Description
The apolipoprotein A-I-mediated signaling pathway (GO:0038027) is a biological process in which apolipoprotein A-I (ApoA-I), the principal protein component of high-density lipoprotein (HDL), binds to cellular acceptors and triggers intracellular signals that regulate lipid handling and cholesterol efflux. This pathway is central to reverse cholesterol transport, the process by which peripheral cells, especially macrophages, eliminate excess cholesterol and return it to the liver for excretion. Because ApoA-I is the major structural and functional apolipoprotein of HDL, its signaling activity is directly tied to atheroprotective mechanisms and cardiovascular health. Researchers study GO:0038027 to understand how cells sense and respond to HDL, how cholesterol homeostasis is maintained, and how defects in this process contribute to disease. The pathway is experimentally tractable: ApoA-I-mediated cholesterol efflux can be measured in cultured cells, and its key mediators such as ABCA1 and ABCA7 are regulated by nuclear receptors and sterol-sensing transcription factors. This article synthesizes the authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of the pathway, its genes, its disease relevance, and the CRISPR-based methods used to dissect it.
apolipoprotein A-I-mediated signaling pathway At A Glance
| GO ID | GO:0038027 |
|---|---|
| GO term | apolipoprotein A-I-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | ApoA-I-triggered signaling that promotes cholesterol efflux and lipid homeostasis, primarily via ABCA1 and related transporters |
| Key mediators | APOA1, ABCA1, ABCA7, LXR, SREBP2, PPAR-gamma |
| Cellular context | Macrophages, hepatocytes, and other peripheral cells involved in reverse cholesterol transport |
| Disease relevance | Atherosclerosis, cardiovascular disease, cerebral hypoperfusion, and lipid disorders |
| Research methods | Cholesterol efflux assays, gene expression analysis, CRISPR knockout/knock-in, and pharmacological modulation |
What Is GO:0038027?
GO:0038027, apolipoprotein A-I-mediated signaling pathway, is defined as the series of molecular events and cellular responses initiated when apolipoprotein A-I (ApoA-I) interacts with a cell and activates signal transduction, most prominently leading to cholesterol efflux and related lipid-homeostatic responses. In practice, the term captures the signaling and transport functions triggered by ApoA-I, including the activation of ABCA1-dependent cholesterol efflux and downstream transcriptional programs that maintain cellular cholesterol balance.
Why Is apolipoprotein A-I-mediated signaling pathway Important in Cell Biology?
GO:0038027 is important because it defines the molecular interface between HDL and cellular cholesterol metabolism, a process that protects against atherosclerosis and cardiovascular disease. Understanding how ApoA-I signals through ABCA1 and related transporters provides mechanistic insight into reverse cholesterol transport, a major atheroprotective pathway. Because the pathway is regulated by nuclear receptors such as LXR and by sterol-sensing factors like SREBP2, it also serves as a model for studying how cells integrate lipid signals with transcriptional control. Defects in ApoA-I-mediated signaling are associated with impaired cholesterol efflux, lipid accumulation, and vascular pathology, making it a high-value target for therapeutic and gene-editing research.
• Central to reverse cholesterol transport, the process by which peripheral cells remove excess cholesterol.
• Directly linked to atheroprotection because ApoA-I is the major apolipoprotein of HDL.
• Provides a mechanistic framework for understanding ABCA1-dependent cholesterol efflux.
• Connects lipid metabolism to transcriptional regulation via LXR and SREBP2.
• Relevant to macrophage foam cell formation and atherosclerotic plaque development.
• Implicated in cerebral hypoperfusion and age-related vascular cognitive impairment.
• Pharmacologically modifiable by natural compounds such as curcumin and emodin.
• Offers tractable experimental readouts for CRISPR-based gene function studies.
• Serves as a paradigm for studying apolipoprotein-receptor signaling beyond cholesterol transport.
• Supports development of HDL-targeted therapeutics and diagnostic biomarkers.
What Happens During apolipoprotein A-I-mediated signaling pathway?
ApoA-I binding and acceptor engagement
In simple terms: ApoA-I, the main protein on HDL, docks onto cells and starts a signal.
The pathway begins when apolipoprotein A-I (ApoA-I) interacts with cellular acceptors, most notably ABCA1, on the surface of target cells such as macrophages. This interaction is the initiating event that couples HDL to intracellular signaling and cholesterol efflux. In experimental systems, ApoA-I-mediated cholesterol efflux is used as a functional readout of this engagement.
ABCA1 activation and cholesterol efflux
In simple terms: The cell opens a channel-like transporter to pump out excess cholesterol.
ABCA1 is the central transporter in this pathway; its expression and activity determine the efficiency of ApoA-I-mediated cholesterol efflux. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR, linking nuclear receptor signaling to this process. In oxidized LDL-loaded THP1 macrophages, enhancing ABCA1 function increases cholesterol efflux, demonstrating the functional importance of this step.
Transcriptional regulation by LXR and SREBP2
In simple terms: The cell adjusts the amount of transporter protein based on cholesterol levels.
The pathway is transcriptionally controlled: LXR regulates ABC1 gene expression and ApoA-I-mediated cholesterol efflux. In parallel, ABCA7 expression is regulated by cellular cholesterol through the SREBP2 pathway, providing a sterol-sensing layer of control. These regulatory loops ensure that efflux capacity matches cellular cholesterol load.
Pharmacological and dietary modulation
In simple terms: Certain natural compounds can boost the pathway.
Curcumin induces ABCA1 expression and ApoA-I-mediated cholesterol transmembrane transport in chronic cerebral hypoperfusion aging rats, showing that the pathway can be upregulated in vivo. Emodin enhances cholesterol efflux by activating PPAR-gamma in oxidized LDL-loaded THP1 macrophages, further demonstrating pharmacological tractability. These findings support the pathway as a target for therapeutic intervention.
Downstream cellular consequences
In simple terms: The signal changes how the cell handles lipids and other functions.
Beyond cholesterol efflux, ABCA7 is associated with phagocytosis, indicating that ApoA-I-related transporters participate in broader cellular functions. The pathway therefore influences lipid homeostasis, macrophage behavior, and potentially inflammatory responses. These downstream effects connect GO:0038027 to vascular and cerebral disease processes.
Key Genes Involved in GO:0038027 apolipoprotein A-I-mediated signaling pathway
The following genes and proteins are experimentally implicated in the apolipoprotein A-I-mediated signaling pathway and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOA1 | Encodes apolipoprotein A-I, the ligand that initiates the pathway | Central to HDL biology and reverse cholesterol transport |
| ABCA1 | Cholesterol transporter mediating ApoA-I-dependent efflux | Primary effector of the pathway; LXR-regulated |
| ABCA7 | Related transporter regulated by cholesterol via SREBP2 | Links sterol sensing to phagocytosis and lipid handling |
| NR1H3 (LXR) | Nuclear receptor regulating ABC1 expression and efflux | Transcriptional control node for the pathway |
| SREBP2 | Sterol-sensing transcription factor regulating ABCA7 | Connects cholesterol status to transporter expression |
| PPARG | Nuclear receptor activated by emodin to enhance efflux | Pharmacological target for boosting cholesterol efflux |
| APOE | Apolipoprotein involved in lipid transport (contextual) | Relevant to HDL and cholesterol metabolism research |
| SCARB1 | HDL receptor family member (contextual) | Potential modifier of ApoA-I signaling |
| CYP27A1 | Sterol metabolism enzyme (contextual) | Contributes to cholesterol homeostasis |
| ABCB11 | Bile acid transporter (contextual) | Downstream of cholesterol elimination pathways |
| ABCG1 | Cholesterol efflux transporter (contextual) | Cooperates with ABCA1 in macrophage efflux |
| TNF | Inflammatory cytokine (contextual) | May modulate efflux in atherosclerotic settings |
| IL6 | Inflammatory cytokine (contextual) | Relevant to macrophage lipid handling |
| MMP9 | Matrix metalloproteinase (contextual) | Associated with plaque remodeling |
| CD36 | Scavenger receptor (contextual) | Involved in oxidized LDL uptake |
| LPL | Lipoprotein lipase (contextual) | Lipid metabolism modifier |
| CETP | Cholesteryl ester transfer protein (contextual) | HDL metabolism modifier |
| LCAT | Lecithin-cholesterol acyltransferase (contextual) | HDL maturation enzyme |
How Is apolipoprotein A-I-mediated signaling pathway Regulated?
The apolipoprotein A-I-mediated signaling pathway is regulated at multiple levels. Transcriptionally, LXR controls ABC1 gene expression and ApoA-I-mediated cholesterol efflux, integrating nuclear receptor signaling with lipid homeostasis. Cellular cholesterol status regulates ABCA7 expression through the SREBP2 pathway, providing a sterol-sensing feedback mechanism. Pharmacologically, PPAR-gamma activation by emodin enhances cholesterol efflux in macrophages, indicating that nuclear receptor signaling can upregulate the pathway. In vivo, curcumin induces ABCA1 expression and ApoA-I-mediated cholesterol transmembrane transport in aging rats with chronic cerebral hypoperfusion, demonstrating that the pathway is responsive to dietary and pharmacological modulation.
apolipoprotein A-I-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCA1 | Atherosclerosis, defective cholesterol efflux | ABCA1 knockout macrophage cell line |
| APOA1 | Cardiovascular disease, impaired reverse cholesterol transport | APOA1 overexpression hepatocyte model |
| ABCA7 | Lipid disorders, phagocytic dysfunction | ABCA7 knockout phagocyte model |
| PPARG | Inflammation, macrophage foam cell formation | PPARG point-mutation macrophage model |
| NR1H3 (LXR) | Dyslipidemia, impaired efflux capacity | LXR knockout cell model |
Atherosclerosis and cardiovascular disease
Impaired ApoA-I-mediated cholesterol efflux leads to cholesterol accumulation in macrophages, foam cell formation, and atherosclerotic plaque development. Because ABCA1 is the central transporter in this pathway, its dysfunction is directly linked to defective reverse cholesterol transport and cardiovascular risk. Enhancing efflux through PPAR-gamma activation or ABCA1 upregulation is therefore a therapeutic strategy under investigation.
Cerebral hypoperfusion and vascular cognitive impairment
In chronic cerebral hypoperfusion aging rats, curcumin induces ABCA1 expression and ApoA-I-mediated cholesterol transmembrane transport, suggesting that the pathway is relevant to brain lipid homeostasis under ischemic stress. This links GO:0038027 to cerebrovascular pathology and age-related cognitive decline.
Lipid disorders and phagocytic dysfunction
ABCA7 expression is regulated by cellular cholesterol through SREBP2 and is associated with phagocytosis, connecting the pathway to lipid disorders and immune cell function. Dysregulation of this transporter may impair both cholesterol handling and pathogen clearance.
From apolipoprotein A-I-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ABCA1 loss abolish ApoA-I-mediated efflux? | ABCA1 knockout cell line |
| Does LXR regulate ABC1 expression? | LXR knockout or knockdown model |
| Does PPAR-gamma activation enhance efflux? | PPARG point-mutation or overexpression model |
| Does ABCA7 respond to cholesterol via SREBP2? | ABCA7 knockout with sterol manipulation |
| Can curcumin upregulate ABCA1 in vivo? | APOA1/ABCA1 knock-in or overexpression animal model |
| Does ApoA-I signaling affect phagocytosis? | ABCA7 tagged knock-in phagocyte model |
How to Study the apolipoprotein A-I-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cholesterol efflux assay | ApoA-I-mediated cholesterol removal | Macrophage and hepatocyte models |
| qPCR | ABCA1, ABCA7, LXR target gene expression | Transcriptional regulation studies |
| Western blot | Protein levels of ABCA1 and related transporters | Validation of knockout or overexpression |
| CRISPR knockout | Loss-of-function effects on efflux | Causal gene testing |
| CRISPR knock-in | Tagged or mutant transporter function | Localization and interaction studies |
| Pharmacological treatment | Effect of compounds on efflux | Drug discovery and mechanism studies |
| Animal model | In vivo pathway activity | Cerebral hypoperfusion and aging studies |
| Phagocytosis assay | ABCA7-associated phagocytic function | Immune cell biology |
Cholesterol efflux assays
Cholesterol efflux assays measure the ability of ApoA-I to promote removal of labeled cholesterol from cells, providing a direct functional readout of GO:0038027. These assays are widely used in macrophage models and can be combined with pharmacological treatments such as curcumin or emodin.
Gene expression analysis
Quantitative PCR and reporter assays are used to measure ABCA1, ABCA7, and LXR target gene expression in response to ApoA-I or cholesterol loading. These methods reveal the transcriptional regulation of the pathway by LXR and SREBP2.
CRISPR-based functional genomics
CRISPR knockout, point mutation, and knock-in models allow precise dissection of gene function in the pathway. For example, ABCA1 knockout cells can confirm its essential role in ApoA-I-mediated efflux, while ABCA7 knockouts can test its role in phagocytosis.
Pharmacological and in vivo studies
Animal models of chronic cerebral hypoperfusion and oxidized LDL-loaded macrophages are used to test whether compounds such as curcumin or emodin modulate the pathway. These studies connect molecular mechanisms to disease phenotypes.
How CRISPR Can Be Used to Study GO:0038027 apolipoprotein A-I-mediated signaling pathway
Knockout
CRISPR knockout of ABCA1 or ABCA7 can definitively test their requirement in ApoA-I-mediated signaling and cholesterol efflux. Loss-of-function models are essential for establishing causality in the pathway.
Point Mutation
Point mutations in ABCA1 or PPARG can mimic disease-associated variants or disrupt specific functional domains, allowing precise structure-function analysis of the pathway. These models help distinguish transport activity from signaling functions.
Knock-in
Knock-in of tagged or fluorescently labeled transporters enables real-time tracking of ABCA1 or ABCA7 localization and trafficking during ApoA-I stimulation. This approach is valuable for understanding dynamic regulation.
Overexpression
Overexpression of APOA1, ABCA1, or PPARG can enhance pathway activity and is used to study gain-of-function effects on cholesterol efflux and disease phenotypes. Such models are useful for therapeutic target validation.
How EDITGENE Supports apolipoprotein A-I-mediated signaling pathway Research
Researchers studying apolipoprotein A-I-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in cholesterol efflux, transcriptional regulation, or disease progression. EDITGENE provides the full spectrum of CRISPR cell-model services to enable that causal work.
Contact EDITGENE today to design your custom CRISPR model for apolipoprotein A-I-mediated signaling pathway research.
Frequently Asked Questions About apolipoprotein A-I-mediated signaling pathway
What is GO:0038027?
GO:0038027 is the apolipoprotein A-I-mediated signaling pathway, a biological process in which ApoA-I triggers cellular signaling and cholesterol efflux, primarily through ABCA1.
What genes are involved in apolipoprotein A-I-mediated signaling pathway?
Key genes include APOA1, ABCA1, ABCA7, NR1H3 (LXR), SREBP2, and PPARG.
How does ApoA-I mediate cholesterol efflux?
ApoA-I interacts with ABCA1 on the cell surface, activating a transport process that removes excess cholesterol from cells.
What is the role of ABCA1 in this pathway?
ABCA1 is the central transporter; its expression and activity determine the efficiency of ApoA-I-mediated cholesterol efflux and are regulated by LXR.
How is ABCA7 related to this pathway?
ABCA7 is regulated by cellular cholesterol through SREBP2 and is associated with phagocytosis, linking it to lipid handling and immune function.
Can natural compounds enhance this pathway?
Yes, curcumin induces ABCA1 expression and ApoA-I-mediated cholesterol transport, and emodin enhances efflux via PPAR-gamma activation.
What diseases are linked to defective ApoA-I signaling?
Atherosclerosis, cardiovascular disease, and cerebral hypoperfusion are associated with impaired ApoA-I-mediated cholesterol efflux.
How can I study GO:0038027 in the lab?
Cholesterol efflux assays, gene expression analysis, and CRISPR knockout or knock-in models are commonly used.
Does LXR regulate this pathway?
Yes, LXR regulates ABC1 gene expression and ApoA-I-mediated cholesterol efflux.
What CRISPR models are available for this pathway?
EDITGENE offers knockout, point mutation, knock-in, and overexpression models for genes such as ABCA1, ABCA7, and PPARG.
Conclusion
GO:0038027, the apolipoprotein A-I-mediated signaling pathway, is a fundamental biological process linking HDL biology to cellular cholesterol homeostasis and cardiovascular health. Its core mediators, including ABCA1, ABCA7, LXR, and PPARG, are experimentally tractable and responsive to pharmacological modulation. CRISPR-based cell models provide powerful tools to dissect the causal roles of these genes in health and disease, and EDITGENE offers comprehensive services to support such research.
References
- 1. Tian M et al.. 2013. Curcumin induces ABCA1 expression and apolipoprotein A-I-mediated cholesterol transmembrane in the chronic cerebral hypoperfusion aging rats.. Am J Chin Med 41(5):1027-42 PMID: 24117066
- 2. Schwartz K et al.. 2000. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR.. Biochem Biophys Res Commun 274(3):794-802 PMID: 10924356
- 3. Fu X et al.. 2014. Emodin enhances cholesterol efflux by activating peroxisome proliferator-activated receptor-γ in oxidized low density lipoprotein-loaded THP1 macrophages.. Clin Exp Pharmacol Physiol 41(9):679-84 PMID: 24837536
- 4. Iwamoto N et al.. 2006. ABCA7 expression is regulated by cellular cholesterol through the SREBP2 pathway and associated with phagocytosis.. J Lipid Res 47(9):1915-27 PMID: 16788211
